Otsuka Pharmaceutical India Pvt. Ltd.

What Otsuka Pharmaceutical India Pvt. Ltd. does

Otsuka Pharmaceutical India Private Limited (OPI) is a fully-owned subsidiary of Japan's Otsuka Pharmaceutical Factory, Inc. (OPF), headquartered in Ahmedabad, Gujarat, and operating a state-of-the-art manufacturing facility in Sanand District with a workforce of 900+ people. The company manufactures and markets intravenous (IV) and clinical nutrition pharmaceutical products across nine therapeutic segments: basic IV infusions, parenteral nutrition (PN), enteral nutrition (EN), anti-infectives, oncology, pain management, plasma volume expanders, special IV infusions, and sterilised water for injections. Its branded franchises include CELEMIN (amino acid solutions for renal, hepatic, infant, and standard care), CELEPID (fat emulsions), HINEX (enteral nutrition supplements for diabetic, standard, and high-protein needs), TNA-PERI (total nutrient admixture combipack), Leniol and IBUDRIP (pain management), and Drocid (oncology). OPI claims its products are administered to 1 in 5 patients in India (Internal Survey Report).

The business model is B2B pharmaceutical manufacturing and direct sales: a pan-India domestic sales force covering all Indian states sells to hospitals and healthcare facilities, while a parallel international distribution channel exports to 60+ countries. The Ahmedabad facility carries an unusually broad regulatory stack — WHO GMP, PIC/S, ANVISA, INVIMA, NPRA, GCC, DIGEMID, FDA Ghana, PMPB, and MH Iraq — which functions as the foundation for both export reach and Indian formulary acceptance. Revenue is generated through product sales under hospital and institutional procurement; pricing is not publicly disclosed. The distribution architecture is a direct enterprise field-sales model domestically, with separate international distribution for exports.

OPI originated in 2013 as a joint venture, became a wholly Japanese-owned MNC in 2017, and transitioned to full OPF ownership in 2023 alongside product launches including BFLUID and CELEMIN Infant. Recent strategic activity includes oncology entry (Drocid), pain-management line extension (IBUDRIP), and the parent OPF's November 2024 joint venture with ICU Medical to consolidate North American IV solutions — positioning OPI's Ahmedabad site as a key node in the group's emerging-markets and export supply network. There is no disclosed AI/ML capability, no public revenue disclosure, and no venture-capital or public-shareholder involvement; OPI operates as a privately held captive manufacturer within the Otsuka Group.

Name

Otsuka Pharmaceutical India Pvt. Ltd.

Legal name

Otsuka Pharmaceutical India Private Limited

Website

https://otsukapharma.in

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Otsuka Pharmaceutical India (OPI) is a fully-owned Ahmedabad-based subsidiary of Japan's Otsuka Pharmaceutical Factory, manufacturing IV infusions, parenteral nutrition, enteral nutrition, anti-infectives, oncology, and pain management products for Indian hospitals and exports to 60+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Intravenous nutrition products
• Pharmaceutical infusion manufacturing
• Parenteral nutrition solutions
• Enteral nutrition supplements
• Clinical infusion therapy

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Manufacturing and marketing of pharmaceutical products in multiple therapeutic segments including IV nutrition products, infusions, anti-infectives, oncology, pain management, and enteral nutrition. Revenue generated through product sales to healthcare facilities and professionals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Otsuka Pharmaceutical India Pvt. Ltd. (OPI) manufactures and markets pharmaceutical infusion products across multiple therapeutic segments, including intravenous (IV) solutions, parenteral nutrition (amino acid solutions and fat emulsions), enteral nutrition supplements, anti-infectives, pain management infusions, oncology infusions, plasma volume expanders, and sterilised water for injections. The company operates a state-of-the-art manufacturing facility near Ahmedabad and supplies branded products such as CELEMIN, CELEPID, HINEX, Leniol, and BFLUID to hospitals and healthcare professionals.

Product overview

Otsuka Pharmaceutical India Private Limited (OPI) is a fully-owned subsidiary of Otsuka Pharmaceutical Factory, Inc. (OPF), Japan, specializing in intravenous (IV) nutrition products and pharmaceutical infusions. The company operates as a single unified product portfolio with multiple therapeutic segments including Basic Intravenous (IV) Infusions, Parenteral Nutrition (PN), Enteral Nutrition (EN), Anti-infectives, Pain Management, Oncology, Plasma volume expanders, Special Intravenous (IV) Infusions, and Sterilised Water for Injections. Key product lines include the CELEMIN family (amino acid solutions for renal, hepatic, and infant care), CELEPID (fat emulsions), HINEX (enteral nutrition supplements), and various IV infusion solutions like NS, DNS, and 5D. OPI is a leader in IV nutrition products in India, serving both domestic and international markets across 60+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• CELEMIN: Parenteral amino acids solutions and injections product line including CELEMIN 10 PLUS, CELEMIN 5S, CELEMIN NEPHRO 7%, CELEMIN HEPA 8%, CELEMIN Infant, CELEMIN 5S PLUS
• CELEPID
• HINEX
• Leniol
• BFLUID
• TNA-PERI

Products and services

• CELEMIN Parenteral Amino Acids Range Parenteral amino acid injection solutions designed for hospital and clinical use in patients requiring intravenous nutrition, including specialised formulations for renal, hepatic, infant, and standard care.
• CELEPID Intravenous Fat Emulsion Range Intravenous fat emulsions (10% and 20% with medium and long chain triglycerides) used as part of total parenteral nutrition for hospitalised patients.
• HINEX Enteral Nutrition Range Enteral nutrition powdered supplements for oral or tube feeding including standard, diabetic-friendly, synbiotic, and high-protein formulations for hospital and home-care patients.
• Basic IV Infusions (NS, DNS, 5D, HAFNOR) Sterile basic intravenous solutions (sodium chloride, glucose, dextrose-saline combinations) for fluid and electrolyte replenishment in hospitals and clinical settings.
• Anti-infective Infusions (OPLEV, Metris, Ciprox, LinoDrip) Intravenous antibiotic infusion formulations including levofloxacin, metronidazole, ciprofloxacin, and linezolid for treating bacterial infections in hospitalised patients.
• Pain Management Infusions (Leniol, IBUDRIP) Intravenous analgesic infusions (paracetamol and ibuprofen) used for pain management in hospitals.
• Oncology Infusion (Drocid) Zoledronic acid intravenous infusion (4 mg/100mL) used in oncology supportive care and treatment of bone-related conditions.
• Plasma Volume Expander (Micropan-40 NS) Plasma volume expander solution used for fluid resuscitation and volume replacement therapy in hospitalised patients.
• Special IV Infusions (VITRINAL, PHYSIOMAX, FLUSODEX-45) Specialised intravenous solutions (hypertonic saline, multiple electrolytes, and chloride-glucose combinations) for advanced clinical and critical care settings.
• Sterilised Water for Injections (SuperAmp) Sterilised water for injections in small-volume ampoules (5ml, 10ml) used as a diluent or solvent for reconstitution of injectable medications in clinical settings.
• TNA-PERI Total Nutrient Admixture Combipack total nutrient admixture (TNA) product combining amino acids, glucose, and fat emulsion in a single package for perioperative parenteral nutrition.
• BFLUID Infusion Combined infusion of 3% amino acids, 7.5% glucose, electrolytes, and vitamin B1 for parenteral nutrition support in clinical settings.

Quantifiable outcome

• 1 in 5 patients in India is administered Otsuka products
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• ICU MedicalcoreStrategic or Co-development Partner · 12 November 2024Otsuka Pharmaceutical Factory America (subsidiary of OPF) and ICU Medical established a joint venture for IV solution business in North America. OPFA obtained 60% shares of the new company. ICU Medical transferred its IV solution business to the new company. The joint venture combines Japan's largest IV solution manufacturer OPF with ICU Medical's North American manufacturing capabilities.
• Japan Sport Council (JSC)flagshipStrategic or Co-development Partner · 1 August 2023JSC and Otsuka Holdings launched TCRP NEXT, a collaborative project for continued research into conditioning to enhance sustainable international competitiveness in sports. The project publishes Total Conditioning Guidelines for Athletes and continues research into total conditioning. Results will be applied to boosting sports performance and raising awareness for enhanced life performance for the general public.
• Tokushima PrefecturecoreStrategic or Co-development Partner · 27 July 2023Otsuka Pharmaceutical Co., Ltd. finalized a collaborative agreement with Tokushima Prefecture to contribute to realization of a sustainable society through promotion of horizontal 'bottle-to-bottle' recycling of PET bottles. Working with 12 participating municipal entities to develop and promote bottle-to-bottle recycling initiatives.
• Toyota Tsusho CorporationcoreStrategic or Co-development Partner · 1 February 2023Toyota Tsusho processes recycled PET bottles into high-quality PET material for use by Otsuka group companies and other beverage manufacturers. Partner in PET bottle recycling initiative with Tokushima Prefecture and municipal entities.
• Shikoku Godo Tsuun K.K.minorStrategic or Co-development Partner · 1 February 2023Shikoku Godo Tsuun transports collected PET bottles from municipal entities to Toyota Tsusho recycling facilities as part of the bottle-to-bottle recycling initiative in Tokushima Prefecture.
• Otsuka Pharmaceutical Factory, Inc. (OPF), JapanflagshipOthersParent company - OPI is a fully-owned subsidiary of Otsuka Pharmaceutical Factory, Inc. (OPF), Japan. OPF is Japan's largest IV solution manufacturer. OPI manufactures and markets products in Indian and overseas markets under the OPF umbrella.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Emerging players

• AdvaCare Pharma: Manufacturer and distributor of pharmaceutical products including IV infusions and injectables, with strong presence across emerging markets (Africa, Asia, Latin America) — comparable export-market strategy to OPI's 60+ country reach.

Direct peers

• Aculife Healthcare (formerly Claris Injectables): Major Indian sterile injectable and IV infusion manufacturer competing in the same hospital procurement and tender processes; comparable product breadth in basic IVs and specialty injectables.
• Claris Lifesciences (now Aculife Healthcare): Aculife (formerly Claris) is one of India's largest sterile injectable and IV fluid manufacturers with substantial hospital-channel presence. Directly comparable product categories and competitive overlap in domestic Indian tenders.
• Marck Biosciences: Indian manufacturer of large-volume parenterals (LVPs), IV fluids, and small-volume injectables serving hospitals in India and regulated export markets — direct overlap in core IV portfolio.
• Fresenius Kabi India: Fresenius Kabi is one of the largest global manufacturers of IV infusion, parenteral/enteral nutrition, and clinical nutrition products — a direct competitor to OPI in both the Indian hospital channel and across the same export markets in Latin America, Asia, and Africa.
• B. Braun Medical India: B. Braun is a global leader in IV solutions, infusion therapy, and clinical nutrition with established Indian manufacturing and a pan-India hospital sales force — directly comparable product portfolio (basic IVs, PN, EN) and overlapping customer base.
• Baxter India: Baxter is a global IV solutions and clinical nutrition major with significant Indian operations and hospital channel presence. Competes head-to-head with OPI across IV fluids, parenteral nutrition, and specialty injectable products.
• Eurolife Healthcare: Indian manufacturer of IV infusions, sterile injectables, and pharmaceuticals — competes with OPI for hospital contracts in India and emerging-market exports.

Regional players

• Albert David Ltd: Indian pharmaceutical company with IV infusions and parenteral products focused primarily on the domestic Indian market. Overlapping product categories and hospital channel, but smaller international footprint than OPI.

Others

• DKSH (Healthcare distribution): Market expansion services provider for healthcare companies across Asia, including distribution, regulatory, and marketing services for pharma manufacturers — relevant peer as a partner/adjacent in OPI's emerging-market channel strategy rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/otsuka-india-pvt-ltd

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Pharmaceutical India Pvt. Ltd.